Retatrutide Dosing & Reconstitution Guide
Dosing Protocol
Route: Subcutaneous (clinical trial formulation only) Frequency: Once weekly Dose Range: Phase 2 tested 1, 4, 8, 12 mg weekly SC; optimal dose being determined in Phase 3 Cycle Length: Phase 2 was 48 weeks; Phase 3 ongoing Timing: Same day each week
Titration Schedule
Weeks 1–4: 1–2 mg weekly (initiation) Weeks 5–8: 4 mg weekly Weeks 9–12: 8 mg weekly Weeks 13+ (maintenance): 8–12 mg weekly
Storage
Lyophilized: −20 °C (−4 °F) Reconstituted: 2–8 °C (35.6–46.4 °F) Shelf Life: 28 days
Injection Sites
Abdomen, Thigh
Safety & Contraindications
Safety: GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) Dose-dependent heart rate increases peaking at 24 weeks, declining thereafter
Contraindications: Not yet established -- product is investigational; Likely similar to GLP-1 class: personal/family history of medullary thyroid carcinoma, MEN2 (precautionary); Pregnancy (based on GLP-1 class)
Related Products
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Related Research News
Retatrutide Clinical Trial Results: Phase III TRIUMPH Data Shows Significant Weight Loss
Early reports from the Phase III TRIUMPH-1 trial suggest retatrutide, a novel triple agonist, has delivered substantial weight loss outcomes. These retatrutide clinical trial results indicate a potential shift in obesity treatment research, though full data analysis is pending.
Retatrutide Phase III TRIUMPH-1 Results: Unprecedented Weight Loss Reported at ADA26
Early reports from the American Diabetes Association 2026 meeting suggest retatrutide delivered unprecedented weight loss in the Phase III TRIUMPH-1 trial. Researchers and industry professionals are closely watching these retatrutide clinical trial results for implications in obesity and metabolic disease treatment.
Retatrutide Monthly Research Cost in Australia Breakdown
Researching Retatrutide (LY3437943), the most advanced triple GLP-1/GIP/glucagon receptor agonist, involves costs that vary by vial size, dose, and frequency. In Australia, a 10mg vial costs $129.99 AUD ($13.00/mg), while a 20mg vial is $199.99 AUD ($10.00/mg). Supplies like bacteriostatic water and needles add to monthly expenses, with planning around a 4-week reconstituted stability window essential to minimize waste.